X
Sanofi builds case for Toujeo in younger type 1 diabetics
https://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
insulin
One Drop and MannKind team for inhalable insulin trial
Trial to investigate One Drop’s diabetes management solution with MannKind’s Afrezza.
Novo hopes hypoglycaemia data will boost Tresiba
Lower severe hypo risk compared with Lantus – but no cardiac benefit.
Lilly and Boehringer biosimilar undercuts Lantus by 15%
Sanofi under pressure following long-awaited biosimilar launch.
Novo to expand world’s biggest insulin production site
World’s largest insulin plant is to get bigger.
Sanofi’s diabetes combo on target for showdown with Novo
Rival insulin and GLP-1 combinations under review in US.
1 2